SCHEMBL15978468

SCHEMBL15978468

Cc1ccc2c(O)cc(O)nc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 2/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NQO2 P16083 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRM2 Q14416 2/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
DHODH Q02127 1/20 0.39
ACHE P22303 4/20 0.39
BCHE P06276 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11401003 0.84 ELANE (0.49) TRPA1MAPTLMNATP53MEN1
SCHEMBL6593684 0.84 CYP1A2 (0.50) TRPA1MAPTLMNATP53NQO2
SCHEMBL30351269 0.81 DHODH (0.43) TRPA1MAPTLMNATP53MEN1
SCHEMBL29029739 0.77 ADRB2 (0.45) MAPTLMNAGAAHPGDCYP1A2
SCHEMBL2905327 0.77 GRM2 (0.49) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL24777192 0.76 MPO (0.41) MEN1KMT2AALOX15HPGDCYP1A2
SCHEMBL20793006 0.76 NQO2 (0.41) TRPA1MAPTLMNANQO2CYP1A2
SCHEMBL4173614 0.76 CYP1A2 (0.50) TRPA1MAPTLMNAKMT2ACYP1A2
SCHEMBL8127677 0.76 POLB (0.47) MAPTMEN1GAAKMT2AALOX15
SCHEMBL29892219 0.76 CYP1A2 (0.41) TRPA1MAPTLMNANQO2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873694-B2 Imidazole quinoline-based immune system modulators JANUS BIOTHERAPEUTICS, INC. (US) 2018-01-23 US disclosed
US-20140242121-A1 NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS JANUS BIOTHERAPEUTICS, INC. (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140242121-A1 NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS IRF3, HLA-DRB1, IFNG TRPA1 973/4885MAPT 12/4885LMNA 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.